Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

1.860 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
We have all of the biggest pre-market stock movers that traders need to know about on Friday with the latest news breakdowns! 
Via InvestorPlace
News headline image
CMND Stock Earnings: Clearmind Medicine Reported Results for Q2 2024 ↗
Clearmind Medicine just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Nasdaq Edges Lower; Morgan Stanley Earnings Top Views ↗
 
Via Benzinga
News headline image
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Crude Oil Down 1%; Bank of America Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Why Is SciSparc (SPRC) Stock Up 25% Today? ↗
SciSparc stock is up on Tuesday as SPRC investors learn of the company filing a new patent covering its weight loss treatment. 
Via InvestorPlace
Topics Intellectual Property
News headline image
Dow Jumps 400 Points; US Retail Sales Flat For June ↗
 
Via Benzinga
Topics Stocks
News headline image
Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Why Psychedelic-Pharma Clearmind Medicine Stock Is Moving Higher ↗
Clearmind Medicine shares are trading higher Friday after the company announced advancement in its proprietary MEAI-based binge behavior regulator program through the granting of patent approval in... 
Via Benzinga
Topics Intellectual Property
News headline image
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Day Trading My Way From Red To Green ↗
I set daily profit goals and max loss limits to manage my risk. My daily goal is $5,000, and I cap my daily loss at the same amount. 
Via Talk Markets
News headline image
Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
What's Going On With Clearmind Medicine Stock Tuesday? ↗
Clearmind said its alcohol substitute was granted patents in the U.S., India and Europe. The company also highlighted that the no/low alcohol category is forecasted to grow at a volume CAGR of more... 
Via Benzinga
Topics Intellectual Property
News headline image
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Why Clearmind Medicine Stock Is Moving Higher ↗
Clearmind Medicine shares are up Tuesday after the company announced it signed an exclusive patent licensing agreement with Yissum Research Development. 
Via Benzinga
Topics Intellectual Property
News headline image
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Clearmind Applies to Cease Being a Reporting Issuer in Canada
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.